Brooks Mays, MD
Endocrinology, Diabetes & Metabolism · Southern Pines, NCNPI 1124134010
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $28,256 of the $40,382 with a category attached, or 70.0%. Johnson & Johnson accounts for 60.6% of it on its own, with 56 other manufacturers making up the rest. Reporting peaked in 2019 at $25,878 and has fallen 95.8% since, to $1,092 in 2025.
Across 719 payments — averaging $56.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$24K
- AbbVie$5K
- Lilly USA, LLC$2K
- Novo Nordisk$1K
- Sanofi-aventis U.S. LLC$830
- Amgen$693
- plus $7K from 51 others
What the payments were for
- Speaking & faculty fees$28,25670%
- Travel & lodging$3121%
- Food & beverage$11,75729%
- Education$570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVOKANA$24,015
- Synthroid$4,500
- MINIMED 780G$125
- Korlym$121
How this compares
$40,382 in reported general payments places this provider in the 85th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 175 | $201,253 |
| JardianceEmpagliflozin | 141 | $141,344 |
| MounjaroTirzepatide | 125 | $133,545 |
| TrulicityDulaglutide | 65 | $96,710 |
| JanuviaSitagliptin Phosphate | 102 | $78,727 |
| Tresiba Flextouch U-200Insulin Degludec | 55 | $68,377 |
| Humulin R U-500Insulin Regular, Human | 33 | $52,338 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 27 | $45,174 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 29 | $43,143 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $35,234 |
| Tresiba Flextouch U-100Insulin Degludec | 52 | $32,545 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $29,511 |
| NovologInsulin Aspart | 83 | $23,981 |
| SynthroidLevothyroxine Sodium | 318 | $23,631 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 114 | $21,680 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $1,696 | $244,398265 claims |
| Novo NordiskOzempic, Novolog | $1,315 | $225,234258 claims |
| Boehringer IngelheimJardiance, Tradjenta | $605 | $157,425152 claims |
| MerckJanuvia | $197 | $78,727102 claims |
| AbbVieSynthroid, Armour Thyroid | $4,775 | $37,768477 claims |
| AstraZenecaFarxiga | $529 | $20,67319 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $114 | $10,9901,198 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $193 | $2,30341 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Southern Pines
- Mark WarrenGreenville$915K
- Thomas OconnellBurlington$805K
- Corey BerlinRaleigh$742K
- Michael FavoritoWilmington$723K
- Stephen SouthGreensboro$624K
- Richard DoddAsheville$526K
- Wendy LaneAsheville$487K
- Victor MarlarAsheville$483K
- John BuseChapel Hill$460K
- Denis BeckerRaleigh$459K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.